Micromet, Inc. (MITI) said it has entered into an agreement for the process development and manufacture of blinatumomab with Lonza AG. (LZAGF.PK).
As per the terms of the agreement, Lonza will manufacture blinatumomab for clinical trials. In addition, Lonza will develop the commercial scale process and will supply blinatumomab for the market if so requested by Micromet.
Blinatumomab is a BiTE antibody for the treatment of various hematologic cancers.
For comments and feedback: editorial@rttnews.com